References
- Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
- Macdonald DR, Cascino TL, Schold SC Jr et al. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol.8, 1277–1280 (1990).
- Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17, 2572–2578 (1999).
- Gilbert MR, Supko JG, Batchelor T et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res.9, 2940–2949 (2003).
- Rao RD, James CD. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin. Oncol.31, 595–604 (2004).
- Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol.22, 133–142 (2004).
- Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst.97, 880–887 (2005).
- Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353, 2012–2024 (2005).
- Guha A, Dashner K, Black PM et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer60, 168–173 (1995).
- Raymond E, Brandes A, Van Osterom A et al. Multicentre Phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC NDDG/BTG Intergroup study. J. Clin. Oncol.22, 17S (2004).
- van den Bent M, Brandes A, Frenay M et al. Multicentre Phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): an EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study. J. Clin. Oncol.23, 16S (2005).
- Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol.16, 1702–1708 (2005).
- Reardon DA, Egorin MJ, Quinn JA et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol.23, 9359–9368 (2005).
- Kleihues P, Louis DN, Scheithauer BW. et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol.61, 215–225 (2002).
- Goldbrunner RH, Bendszus M, Wood J et al. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery55, 426–432 (2004).
- Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. J. Clin. Oncol.24, 18S (2006).
- Vogelzang NJ. Treatment options in metastatic renal carcinoma: an embarrassment of riches. J. Clin. Oncol.24, 1–3 (2006).